Get the Stockscreener App
5.35
2.55%
-0.14
Pre-market:
5.26
-0.09
-1.68%
Lifecore Biomedical Inc stock is traded at $5.35, with a volume of 155.38K.
It is down -2.55% in the last 24 hours and up +21.59% over the past month.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
See More
Previous Close:
$5.49
Open:
$5.6
24h Volume:
155.38K
Relative Volume:
0.46
Market Cap:
$200.68M
Revenue:
$147.12M
Net Income/Loss:
$-33.88M
P/E Ratio:
-5.0362
EPS:
-1.0623
Net Cash Flow:
$2.63M
1W Performance:
-5.48%
1M Performance:
+21.59%
6M Performance:
-30.61%
1Y Performance:
-19.79%
1-Day Range:
$5.25
$5.67
1-Week Range:
$5.25
$5.86
52-Week Range:
$3.625
$8.9799
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Name
Lifecore Biomedical Inc
Sector
Phone
(952) 368-4300
Address
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
5.35 | 205.93M | 147.12M | -33.88M | 2.63M | -1.0623 |
TAK
Takeda Pharmaceutical Co Adr
|
15.66 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.09 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.33 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.27 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Sep-04-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| May-21-25 | Initiated | William Blair | Outperform |
| Sep-05-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-20-23 | Downgrade | Stephens | Overweight → Equal-Weight |
View All
Lifecore Biomedical Inc Stock (LFCR) Latest News
Lifecore Biomedical signs manufacturing deal for neurology product - Investing.com
Lifecore Biomedical Signs Agreement for Tech Transfer and Commercial Production of Neurological Injectable Product - Quiver Quantitative
Seventh late-stage project adds neurology deal for Lifecore Biomedical - Stock Titan
LFCR Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Investor SentimentPreliminary Results - newsline.com
Lifecore Biomedical (LFCR) Stock Draws Fresh Price Target Split After FY26 Outlook - Yahoo Finance
Trading Systems Reacting to (LFCR) Volatility - Stock Traders Daily
Lifecore Biomedical (LFCR) director awarded 25,907 RSUs - Stock Titan
Lifecore Biomedical (LFCR) director receives 25,907-share restricted stock award - Stock Titan
Lifecore Biomedical (LFCR) director receives 25,907 restricted stock units - Stock Titan
Lifecore Biomedical (LFCR) director receives 25,907-share restricted stock unit grant - Stock Titan
Lifecore Shareholders Approve New 2026 Stock Incentive Plan - TipRanks
Lifecore Biomedical (NASDAQ: LFCR) wins approval for 2026 stock plan - Stock Titan
LFCR Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock Rises Despite WeaknessAnnual Financial Report - newsline.com
Lifecore Biomedical Signs Tech Transfer Agreement for Ophthalmic - Contract Pharma
Lifecore Biomedical signs ophthalmic manufacturing deal - Investing.com UK
Lifecore Biomedical, Inc. Signs Manufacturing Services Agreement with Leading Provider of Ophthalmic Disease Management Solutions - marketscreener.com
Lifecore Biomedical signs ophthalmic manufacturing deal By Investing.com - Investing.com South Africa
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer - The Manila Times
Lifecore Biomedical Inc. (LFCR) Q1 2026 Earnings: EPS Misses Estimates by 75.6% as Revenue Remains UndisclosedBuyback Announcement Report - newsline.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical (LFCR) Inches Higher as Stock Approaches Key ResistanceVanna Flow - newsline.com
How The Lifecore Biomedical (LFCR) Narrative Is Shifting On Guidance, Timing And 2028 Expectations - Yahoo Finance
LFCR Q1 2026 Earnings: EPS Falls Short of Estimates as Losses WidenEarnings Season Outlook - The Legal Advocate
LFCR Q1 2026 Earnings: Significant EPS Miss Despite Positive Stock ReactionFinal Results - newsline.com
Lifecore Biomedical (LFCR) Declines 2.6%, Testing Key Support at $4.56Hull Moving Average - The Legal Advocate
LFCR Q1 2026 Earnings: Wider Loss Than Expected Despite Positive Stock ReactionGlobal Trading Community - Newser
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference - Sahm
Lifecore CEO, CFO to meet investors at June 2-4 Chicago conference - Stock Titan
Lifecore Biomedical (LFCR) Q1 2026 Earnings Miss by Significant: Key TakeawaysCollaborative Trading Signals - Newser
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
Lifecore targets 12% revenue CAGR through 2029 as midterm pipeline milestones shift - MSN
LFCR Stock Price, Quote & Chart | LIFECORE BIOMEDICAL INC (NASDAQ:LFCR) - ChartMill
Lifecore reaffirms 2026 guidance of $120M-$125M revenue and $20.5M-$25M adjusted EBITDA while targeting 12% revenue CAGR by 2029 - MSN
Lifecore Biomedical to Participate at CDMO Live Europe - The Manila Times
TradingKey - TradingKey
The sustainable advantages Lifecore Biomedical (LFCR) is developing (+0.42%) 2026-05-10Fast Rising Stocks - newser.com
Number of shareholders of Lifecore Biomedical, Inc. – NASDAQ:LFCR - TradingView
Lifecore Biomedical (LFCR) price target decreased by 25.71% to 6.63 - MSN
LFCR Lifecore Biomedical shares slide 3.83% as Q1 2026 earnings miss estimates by 75.7% despite modest revenue growth.Social Momentum Signals - newser.com
The steady strength in Lifecore Biomedical (LFCR) story (Softens) 2026-05-08Company Analysis - newser.com
Lifecore Biomedical Q1 2026 Earnings Call Transcript - Sahm
Barrington Maintains Lifecore Biomedical(LFCR.US) With Buy Rating, Maintains Target Price $6 - Moomoo
MSN Money - MSN
Lifecore Biomedical: Q1 Earnings Snapshot - theheraldreview.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LFCR) 2026-05-06 - Seeking Alpha
Lifecore Biomedical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Keybanc Initiates Coverage of Lifecore Biomedical (LFCR) with Sector Weight Recommendation - MSN
Lifecore Biomedical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lifecore Biomedical Q1 Earnings Call Highlights - Yahoo Finance
Lifecore Biomedical Inc Stock (LFCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):